RIPK1 and metabolic dysfunction-associated steatotic liver disease: Importantly, RIPK1 inhibition has shown efficacy not only in prophylactic interventions but also in established MASLD, reducing obesity and triglyceride accumulation in the liver (Majdi et al, 2020).